Last reviewed · How we verify

Rémifentamil + KETAMINE — Competitive Intelligence Brief

Rémifentamil + KETAMINE (Rémifentamil + KETAMINE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid + NMDA receptor antagonist combination. Area: Anesthesia.

marketed Opioid + NMDA receptor antagonist combination Mu-opioid receptor (remifentanil); NMDA receptor (ketamine) Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Rémifentamil + KETAMINE (Rémifentamil + KETAMINE) — University Hospital, Clermont-Ferrand. Remifentanil and ketamine together provide rapid-onset anesthesia and analgesia by combining opioid mu-receptor agonism with NMDA receptor antagonism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Rémifentamil + KETAMINE TARGET Rémifentamil + KETAMINE University Hospital, Clermont-Ferrand marketed Opioid + NMDA receptor antagonist combination Mu-opioid receptor (remifentanil); NMDA receptor (ketamine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid + NMDA receptor antagonist combination class)

  1. University Hospital, Clermont-Ferrand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rémifentamil + KETAMINE — Competitive Intelligence Brief. https://druglandscape.com/ci/r-mifentamil-ketamine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: